TaiwanJ Pharmaceuticals has reported positive results from Phase II clinical trial evaluating the efficacy and safety of JKB-122 for the treatment of patients with refractory Autoimmune Hepatitis (AIH).
JKB-122 is currently under development as a small molecule and a long-acting TLR4 antagonist.
The solution has demonstrated anti-fibrotic, immuno-modulating, and anti-inflammatory effects for the treatments of several chronic liver diseases such as non-alcoholic fatty liver disease (NAFLD), autoimmune hepatitis (AIH), and non-alcoholic steatohepatitis (NASH).
Patients enrolled in the Phase II trial showed improvement on the targeted objectives and relevant biomarkers after being treated with JKB-122 for a period of 24 weeks.
TaiwanJ Pharmaceuticals said in a statement: “According to the trial results, the Phase II study has successfully achieved its primary endpoint with the statistical significance (P<0.05) in efficacy compared to the baseline in the responder group, mean change of ALT is -70.0 IU (80.6%), P=0.004.
“In addition, the secondary endpoints of the trial were achieved with the mean change of AST -32.8 IU (67.2%), P=0.022, the mean change of GGT -77.0 IU (66.8%), P=0.033, the mean change of ALP -17.8 IU (29.4 %).
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below formBy GlobalData
“Moreover, the drug JKB-122 is safe and well-tolerated in this study. As an orphan drug designation, the study result of JKB-122 provides a further opportunity for the AIH treatment.”
TaiwanJ enrolled 20 subjects in the US as part of the Phase II trial.
Subjects were treated with a once-daily dose of 5mg JKB-122, which was eventually increased to a monthly dose of up to 40mg JKB-122 in case their ALT performance was not improved during the trial.
The 24-week trial saw 31% of subjects respond positively to the study treatment.